European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 575-582 , June 2010

Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: Preliminary results of a case–control study

  • P. Pessaux

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 88 12 72 58; fax: +33 3 88 12 72 86.
    • ,
  • F. Panaro

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • ,
  • S. Casnedi

      Affiliations

    • Laboratoire d'’anatomie pathologique - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67200 Strasbourg, France
    • ,
  • I. Zeca

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • ,
  • E. Marzano

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • ,
  • P. Bachellier

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • ,
  • D. Jaeck

      Affiliations

    • Centre de Chirurgie Viscérale et de Transplantation - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67098 Strasbourg, France
    • ,
  • M.P. Chenard

      Affiliations

    • Laboratoire d'’anatomie pathologique - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg – Université de Strasbourg, Avenue Molière, 67200 Strasbourg, France

,Accepted 12 April 2010.

References 

  1. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–999
  2. Jaeck D, Pessaux P. Bilobar colorectal liver metastases: treatment options. Surg Oncol Clin N Am. 2008;17:553–568
  3. Nordlinger B, Sorbye H, Collette L, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–1016
  4. Rubbia-Brandt L, Audard V, Sartorelli P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466
  5. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after pre-operative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:845–853
  6. Karoui M, Penna C, Amin-Hashem M, et al. Influence of chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7
  7. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–124
  8. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pre-treatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–853
  9. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072
  10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  12. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593–4602
  13. D’Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case–control study. Ann Surg Oncol. 2006;14:759–765
  14. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96–106
  15. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–2767
  16. Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35:515–520
  17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213
  18. Balzan S, Belghiti J, Farges O, et al. The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824–829
  19. Ozier Y, Pessione F, Samain E, et al. French study group on blood transfusion in liver transplantation. Institutional variability in transfusion practice for liver transplantation. Anesth Analg. 2003;97:671–679
  20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005;41:1313–1321
  21. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31:241–246
  22. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection based on 1568 patients. Cancer. 1996;77:1254–1262
  23. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–321
  24. Parc Y, Dugue L, Farges O, et al. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection. Hepatogastroenterology. 2000;47:1703–1705
  25. Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082–1088
  26. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009;16:35–41
  27. Suc B, Panis Y, Belghiti J, et al. Natural history of hepatectomy. Br J Surg. 1992;79:39–42
  28. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg. 2006 Jan;202(1):199–200
  29. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274–286
  30. Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007 Apr 10;96(7):1037–1042

PII: S0748-7983(10)00098-3

doi: 10.1016/j.ejso.2010.04.010

European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 575-582 , June 2010

Article Tools